Price (delayed)
$6.03
Market cap
$262.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.24
Enterprise value
$269.18M
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
There are no recent dividends present for ABEO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.